Company profile
MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology: Pharmaceutical Preparations
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07459647 | phase2 | recruiting | 2026-03-31 | 2030-02-01 | MapLight Therapeutics | A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia |
| NCT06887192 | phase2 | recruiting | 2025-08-15 | 2027-12-01 | MapLight Therapeutics | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis |
| NCT07038876 | phase2 | completed | 2025-06-27 | 2026-06-04 | MapLight Therapeutics | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia |
| NCT07459660 | phase2 | enrolling_by_invitation | 2026-03-25 | 2029-03-01 | MapLight Therapeutics | An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis |
| NCT05889273 | phase2 | active_not_recruiting | 2023-06-01 | 2027-11-01 | MapLight Therapeutics | ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) |
FDA applications (0)
No records yet.